STRS Ohio’s Cytek Biosciences CTKB Stock Holding History

STRS Ohio’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$142K	Buy	32,000 +5,800	+22%	+$24.8K	﹤0.01%	1742
2026 Q1	$114K	Hold	26,200	–	–	﹤0.01%	1726
2025 Q4	$132K	Hold	26,200	–	–	﹤0.01%	1716
2025 Q3	$90.9K	Hold	26,200	–	–	﹤0.01%	1868
2025 Q2	$89.1K	Hold	26,200	–	–	﹤0.01%	1903
2025 Q1	$105K	Hold	26,200	–	–	﹤0.01%	1657
2024 Q4	$170K	Hold	26,200	–	–	﹤0.01%	1546
2024 Q3	$145K	Buy	+26,200	New	+$149K	﹤0.01%	1642
2023 Q3	–	Sell	-18,300	Closed	-$156K	–	1961
2023 Q2	$156K	Sell	18,300 -50,600	-73%	-$454K	﹤0.01%	1647
2023 Q1	$633K	Buy	68,900 +28,800	+72%	+$310K	﹤0.01%	1147
2022 Q4	$409K	Buy	40,100 +18,400	+85%	+$247K	﹤0.01%	1397
2022 Q3	$319K	Buy	+21,700	New	+$282K	﹤0.01%	1476
2022 Q1	–	Sell	-3,700	Closed	-$60K	–	2156
2021 Q4	$60K	Hold	3,700	–	–	﹤0.01%	1974
2021 Q3	$79K	Buy	+3,700	New	+$87K	﹤0.01%	1983

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

STRS Ohio's CTKB Position: Q2 2026 in Review

STRS Ohio increased its Cytek Biosciences (CTKB) stake by 22% in Q2 2026, buying an estimated $24.8K and bringing the position to 32,000 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

STRS Ohio first reported a position in CTKB in Q3 2021 and has held it in 14 quarters since. The position peaked at $633K in Q1 2023. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

STRS Ohio held 32,000 shares of Cytek Biosciences worth $142K as of Q2 2026.
STRS Ohio bought 5,800 Cytek Biosciences shares in Q2 2026, an estimated $24.8K.
Cytek Biosciences made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1742 holding.
STRS Ohio first reported a position in Cytek Biosciences in Q3 2021 and has held it in 14 quarters since.
STRS Ohio's Cytek Biosciences position peaked at $633K in Q1 2023.
155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.